Management of Coagulopathy in Postpartum Hemorrhage

Abstract

The purpose of this article is to review the use of blood products and hemostatic agents in the management of coagulopathy at the time of postpartum hemorrhage. Blood product administration strategies are broadly reviewed, including the role of the blood bank, the role of massive transfusion protocols, the role of laboratory monitoring, and the role of anesthesia management. Aspects of patient blood management are discussed. The concept refers to an evidence-based, comprehensive, multidisciplinary approach to optimizing the care of patients who might need transfusion and includes measures to avoid or minimize transfusion such as preoperative anemia management, cell salvage, and the use of hemostatic medication to reduce bleeding. The contributions of individual blood components—red blood cells, plasma, cryoprecipitate, and platelets—are described. Current data regarding the complementary role of hemostatic agents—antifibrinolytic agents and clotting factor concentrates—are presented. Two developments in blood component pathogen reduction are introduced.

Keywords

postpartum hemorrhage - coagulopathy - transfusion - patient blood management - blood product - blood component

• References

• 1 James AH, Paglia MJ, Gernsheimer T, Grotegut C, Thames B. Blood component therapy in postpartum hemorrhage. Transfusion 2009; 49 (11) 2430-2433
• 2 Bateman BT, Berman MF, Riley LE, Leffert LR. The epidemiology of postpartum hemorrhage in a large, nationwide sample of deliveries. Anesth Analg 2010; 110 (5) 1368-1373
• 3 Lennox C, Marr L. Scottish Confidential Audit of Severe Maternal Morbidity, 10th Annual Report. Healthcare Improvement Scotland. Edinburgh; July 2014
• 4 Stainsby D, MacLennan S, Thomas D, Isaac J, Hamilton PJ ; British Committee for Standards in Haematology. Guidelines on the management of massive blood loss. Br J Haematol 2006; 135 (5) 634-641
• 5 Main EK, Goffman D, Scavone BM , et al; National Partnership for Maternal Safety; Council on Patient Safety in Women's Health Care. National Partnership for Maternal Safety: Consensus Bundle on Obstetric Hemorrhage. Obstet Gynecol 2015; 126 (1) 155-162
• 6 Lyndon A, Lagrew D, Shields LE, Main E, Cape V. Improving Health Care Response to Obstetric Hemorrhage Version 2.0: A California Quality Improvement Toolkit. Obstetric Hemorrhage Task Force; California Maternal Quality Care Collaborative (CMQCC); Maternal, Child and Adolescent Health Division; Center for Family Health; California Department of Public Health. Sacramento, CA: California Department of Public Health; 2015: 1-179
• 7 Fleming D, Gangopadhyay R, Karoshi M, Arulkumaran S. Maternal deaths from major obstetric hemorrhage in the UK: changing evidence from the confidential enquiries (1985–2011). In: Arulkumaran S, Karoshi M, Keith LG, Lalonde AB, B-Lynch C, eds. A Comprehensive Textbook of Postpartum Hemorrhage, 2nd ed. London: Sapiens Publishing; 2012
• 8 Lilley G, Burkett-St-Laurent D, Precious E , et al. Measurement of blood loss during postpartum haemorrhage. Int J Obstet Anesth 2015; 24 (1) 8-14
• 9 Holcomb JB, Tilley BC, Baraniuk S , et al; PROPPR Study Group. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 2015; 313 (5) 471-482
• 10 Shields LE, Smalarz K, Reffigee L, Mugg S, Burdumy TJ, Propst M. Comprehensive maternal hemorrhage protocols improve patient safety and reduce utilization of blood products. Am J Obstet Gynecol 2011; 205 (4) 368.e1-368.e8
• 11 Collins P, Abdul-Kadir R, Thachil J ; Subcommittees on Women' s Health Issues in Thrombosis and Haemostasis and on Disseminated Intravascular Coagulation. Management of coagulopathy associated with postpartum hemorrhage: guidance from the SSC of the ISTH. J Thromb Haemost 2016; 14 (1) 205-210
• 12 Abdul-Kadir R, McLintock C, Ducloy AS , et al. Evaluation and management of postpartum hemorrhage: consensus from an international expert panel. Transfusion 2014; 54 (7) 1756-1768
• 13 Collins PW, Lilley G, Bruynseels D , et al. Fibrin-based clot formation as an early and rapid biomarker for progression of postpartum hemorrhage: a prospective study. Blood 2014; 124 (11) 1727-1736
• 14 Eddy VA, Morris Jr JA, Cullinane DC. Hypothermia, coagulopathy, and acidosis. Surg Clin North Am 2000; 80 (3) 845-854
• 15 Belfort MA ; Publications Committee, Society for Maternal-Fetal Medicine. Placenta accreta. Am J Obstet Gynecol 2010; 203 (5) 430-439
• 16 Goucher H, Wong CA, Patel SK, Toledo P. Cell salvage in obstetrics. Anesth Analg 2015; 121 (2) 465-468
• 17 Dutton RP, Lee LA, Stephens LS, Posner KL, Davies JM, Domino KB. Massive hemorrhage: a report from the anesthesia closed claims project. Anesthesiology 2014; 121 (3) 450-458
• 18 Dirkmann D, Hanke AA, Görlinger K, Peters J. Hypothermia and acidosis synergistically impair coagulation in human whole blood. Anesth Analg 2008; 106 (6) 1627-1632
• 19 Patient Blood Management. Available at: http://www.aabb.org/pbm/Pages/default.aspx?gclid=CjwKEAiAkvmzBRDQpozmt-uluCQSJACvCd1l6DL9AmmJHLdf3GsOvZV4eWnKHHsejtgiFOESMzZEzBoCpfPw_wcB . Accessed December 26, 2015
• 20 Gombotz H. Patient blood management: a patient-orientated approach to blood replacement with the goal of reducing anemia, blood loss and the need for blood transfusion in elective surgery. Transfus Med Hemother 2012; 39 (2) 67-72
• 21 Murphy MF, Goodnough LT. The scientific basis for patient blood management. Transfus Clin Biol 2015; 22 (3) 90-96
• 22 Vassallo R, Goldman M, Germain M, Lozano M ; BEST Collaborative. Preoperative autologous blood donation: waning indications in an era of improved blood safety. Transfus Med Rev 2015; 29 (4) 268-275
• 23 Yamada T, Mori H, Ueki M. Autologous blood transfusion in patients with placenta previa. Acta Obstet Gynecol Scand 2005; 84 (3) 255-259
• 24 Liumbruno GM, Liumbruno C, Rafanelli D. Autologous blood in obstetrics: where are we going now?. Blood Transfus 2012; 10 (2) 125-147
• 25 AABB Decision Making Process for Transfusion and Transplantation Safety Policies: AABB Statement before the Advisory Committee on Blood Safety and Available at: http://www.aabb.org/advocacy/statements/Pages/statement050109.aspx . Accessed 2009
• 26 Guinn NR, Guercio JR, Hopkins TJ , et al; Duke Perioperative Enhancement Team (POET). How do we develop and implement a preoperative anemia clinic designed to improve perioperative outcomes and reduce cost?. Transfusion 2016; 56 (2) 297-303
• 27 Pavord S, Myers B, Robinson S, Allard S, Strong J, Oppenheimer C ; British Committee for Standards in Haematology. UK guidelines on the management of iron deficiency in pregnancy. Br J Haematol 2012; 156 (5) 588-600
• 28 Shafi D, Purandare SV, Sathe AV. Iron deficiency anemia in pregnancy: intravenous versus oral route. J Obstet Gynaecol India 2012; 62 (3) 317-321
• 29 Kochhar PK, Kaundal A, Ghosh P. Intravenous iron sucrose versus oral iron in treatment of iron deficiency anemia in pregnancy: a randomized clinical trial. J Obstet Gynaecol Res 2013; 39 (2) 504-510
• 30 Froessler B, Cocchiaro C, Saadat-Gilani K, Hodyl N, Dekker G. Intravenous iron sucrose versus oral iron ferrous sulfate for antenatal and postpartum iron deficiency anemia: a randomized trial. J Matern Fetal Neonatal Med 2013; 26 (7) 654-659
• 31 al-Momen AK, al-Meshari A, al-Nuaim L , et al. Intravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy. Eur J Obstet Gynecol Reprod Biol 1996; 69 (2) 121-124
• 32 Bayoumeu F, Subiran-Buisset C, Baka NE, Legagneur H, Monnier-Barbarino P, Laxenaire MC. Iron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route. Am J Obstet Gynecol 2002; 186 (3) 518-522
• 33 Shi Q, Leng W, Wazir R , et al. Intravenous iron sucrose versus oral iron in the treatment of pregnancy with iron deficiency anaemia: a systematic review. Gynecol Obstet Invest 2015; 80 (3) 170-178
• 34 Al RA, Unlubilgin E, Kandemir O, Yalvac S, Cakir L, Haberal A. Intravenous versus oral iron for treatment of anemia in pregnancy: a randomized trial. Obstet Gynecol 2005; 106 (6) 1335-1340
• 35 Wang C, Graham DJ, Kane RC , et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA 2015; 314 (19) 2062-2068
• 36 Waters JH, Biscotti C, Potter PS, Phillipson E. Amniotic fluid removal during cell salvage in the cesarean section patient. Anesthesiology 2000; 92 (6) 1531-1536
• 37 Teare KM, Sullivan IJ, Ralph CJ. Is cell salvaged vaginal blood loss suitable for re-infusion?. Int J Obstet Anesth 2015; 24 (2) 103-110
• 38 Vassallo R, Bachowski G, Benjamin RJ , et al. A Compendium of Transfusion Practice Guidelines, 2nd ed. Washington, DC: American Red Cross; 2013
• 39 Sentilhes L, Vayssière C, Deneux-Tharaux C , et al. Postpartum hemorrhage: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF): in collaboration with the French Society of Anesthesiology and Intensive Care (SFAR). Eur J Obstet Gynecol Reprod Biol 2016; 198: 12-21
• 40 Bonnet MP, Deneux-Tharaux C, Dupont C, Rudigoz RC, Bouvier-Colle MH. Transfusion practices in postpartum hemorrhage: a population-based study. Acta Obstet Gynecol Scand 2013; 92 (4) 404-413
• 41 Cooling L. Going from A to B: the safety of incompatible group A plasma for emergency release in trauma and massive transfusion patients. Transfusion 2014; 54 (7) 1695-1697
• 42 Valsami S, Dimitroulis D, Gialeraki A, Chimonidou M, Politou M. Current trends in platelet transfusions practice: the role of ABO-RhD and human leukocyte antigen incompatibility. Asian J Transfus Sci 2015; 9 (2) 117-123
• 43 Densmore TL, Goodnough LT, Ali S, Dynis M, Chaplin H. Prevalence of HLA sensitization in female apheresis donors. Transfusion 1999; 39 (1) 103-106
• 44 Pavenski K, Freedman J, Semple JW. HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management. Tissue Antigens 2012; 79 (4) 237-245
• 45 WHO. WHO Recommendations for the Prevention and Treatment of Postpartum Haemorrhage. Department of Reproductive Health and Research, World Health Organization; 2012
• 46 Kozek-Langenecker SA, Afshari A, Albaladejo P , et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013; 30 (6) 270-382
• 47 Novikova N, Hofmeyr GJ. Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database Syst Rev 2010; (7) CD007872
• 48 Xu J, Gao W, Ju Y. Tranexamic acid for the prevention of postpartum hemorrhage after cesarean section: a double-blind randomization trial. Arch Gynecol Obstet 2013; 287 (3) 463-468
• 49 Ducloy-Bouthors AS, Jude B, Duhamel A , et al; EXADELI Study Group. High-dose tranexamic acid reduces blood loss in postpartum haemorrhage. Crit Care 2011; 15 (2) R117
• 50 Frimat M, Decambron M, Lebas C , et al. Renal cortical necrosis in postpartum hemorrhage: a case series. Am J Kidney Dis 2016; 68 (1) 50-57
• 51 World Maternal Antibrinolytic Trial (WOMAN) . Available at: https://clinicaltrials.gov/ct2/show/NCT00872469 . Accessed January 25, 2012
• 52 Andersen ND, Bhattacharya SD, Williams JB , et al. Intraoperative use of low-dose recombinant activated factor VII during thoracic aortic operations. Ann Thorac Surg 2012; 93 (6) 1921-1928 , discussion 1928–1929
• 53 Phillips LE, McLintock C, Pollock W , et al; Australian and New Zealand Haemostasis Registry. Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry. Anesth Analg 2009; 109 (6) 1908-1915
• 54 Alfirevic Z, Elbourne D, Pavord S , et al. Use of recombinant activated factor VII in primary postpartum hemorrhage: the Northern European registry 2000-2004. Obstet Gynecol 2007; 110 (6) 1270-1278
• 55 Lavigne-Lissalde G, Aya AG, Mercier FJ , et al. Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial. J Thromb Haemost 2015; 13 (4) 520-529
• 56 Francois KE, Foley MR. Antepartum and postpartum hemorrhage. In: Gabbe S, Niebyl J, Simpson J, eds. Obstetrics: Normal and Problem Pregnancies, 5th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2007: 456-485
• 57 Charbit B, Mandelbrot L, Samain E , et al; PPH Study Group. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 2007; 5 (2) 266-273
• 58 Bolliger D, Szlam F, Molinaro RJ, Rahe-Meyer N, Levy JH, Tanaka KA. Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. Br J Anaesth 2009; 102 (6) 793-799
• 59 Bell SF, Rayment R, Collins PW, Collis RE. The use of fibrinogen concentrate to correct hypofibrinogenaemia rapidly during obstetric haemorrhage. Int J Obstet Anesth 2010; 19 (2) 218-223
• 60 Fenger-Eriksen C, Lindberg-Larsen M, Christensen AQ, Ingerslev J, Sørensen B. Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations. Br J Anaesth 2008; 101 (6) 769-773
• 61 Glover NJ, Collis RE, Collins P. Fibrinogen concentrate use during major obstetric haemorrhage. Anaesthesia 2010; 65 (12) 1229-1230
• 62 Thorarinsdottir HR, Sigurbjornsson FT, Hreinsson K, Onundarson PT, Gudbjartsson T, Sigurdsson GH. Effects of fibrinogen concentrate administration during severe hemorrhage. Acta Anaesthesiol Scand 2010; 54 (9) 1077-1082
• 63 Mallaiah S, Barclay P, Harrod I, Chevannes C, Bhalla A. Introduction of an algorithm for ROTEM-guided fibrinogen concentrate administration in major obstetric haemorrhage. Anaesthesia 2015; 70 (2) 166-175
• 64 Wikkelsø AJ, Edwards HM, Afshari A , et al; FIB-PPH trial group. Pre-emptive treatment with fibrinogen concentrate for postpartum haemorrhage: randomized controlled trial. Br J Anaesth 2015; 114 (4) 623-633
• 65 Tanaka KA, Szlam F. Treatment of massive bleeding with prothrombin complex concentrate: argument for. J Thromb Haemost 2010; 8 (12) 2589-2591
• 66 Seltsam A, Müller TH. Update on the use of pathogen-reduced human plasma and platelet concentrates. Br J Haematol 2013; 162 (4) 442-454
• 67 Wiltshire M, Meli A, Schott MA , et al. Quality of red cells after combination of prion reduction and treatment with the intercept system for pathogen inactivation. Transfus Med 2016; 26 (3) 208-214